Premium
A method for shifting from oral to intramuscular diphenylhydantoin administration
Author(s) -
Wilder B. J.,
Serrano E. E.,
Ramsey Eugene,
Buchanan R. A.
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974163part1507
Subject(s) - oral administration , medicine , intramuscular injection , excretion , urinary system , regimen , phenytoin , plasma levels , plasma concentration , pharmacology , endocrinology , epilepsy , psychiatry
In the first part of this study patients received constant daily doses of diphenylhydantoin (DPH) during oral, intramuscular, and subsequent oral periods. The data demonstrate that there is a profound fall in plasma DPH levels and urinary 5‐(p‐hydroxyphenyl)‐5‐ phenylhydantoin (HPPH) excretion after intramuscular (IM) administration and that this fall is followed by significant rebound when oral administration is resumed. The second part presents data for a regimen, confirmed by clinical and laboratory findings, for switching from oral to IM dosage and back without dramatic changes in plasma DPH levels or urinary HPPH excretion.